European Urology Association (EAU) guidelines recommend immediate radical cystectomy (early RC) for patients with very high-risk (VHR) non-muscle invasive bladder cancer (NMIBC), with bacillus Calmette-Guérin (BCG) recommended only for those who refuse or are unfit for RC.
To describe oncological outcomes following BCG or early RC in a contemporary cohort of patients with VHR NMIBC (EAU criteria).
Patients diagnosed with VHR NMIBC between 2000 and 2020 were identified from our institutional NMIBC registry.
The primary outcomes were overall survival (OS) and cancer-specific mortality (CSM). Secondary outcomes were the progression rate and high-grade recurrence (HGR) rate for patients receiving BCG.
We identified 235 patients with VHR NMIBC, of whom 157 (67%) received BCG and 78 (33%) underwent early RC. The median follow-up was 52.8 mo. OS and CSM rates were 80.2% and 5.3% in the BCG group, and 88.1% and 4.9% in the early RC group, respectively with no significant difference in OS (p = 0.6) or CSM (p = 0.8) between the two groups. Among the patients treated with BCG, 5-yr HGR and progression rates were 41.9% and 17.4%, respectively; 39 patients (25%) underwent delayed RC after BCG. No significant difference in CSM emerged when comparing patients treated with delayed RC (after BCG) with those undergoing early RC (p = 0.86).
Our findings suggest that intravesical BCG can be offered to patients as a resonable alternative to early RC for selected patients with VHR NMIBC.
We evaluated outcomes for patients with very high-risk non-muscle-invasive bladder cancer (NMIBC) treated with BCG (bacillus Calmette-Guérin) versus early surgical removal of the bladder and found no differences in survival. We conclude that BCG could be offered to selected patients with this type of bladder cancer as a reasonable alternative to early bladder removal.
European urology oncology. 2023 Aug 07 [Epub ahead of print]
Roberto Contieri, Patrick J Hensley, Wei Shen Tan, Valentina Grajales, Kelly Bree, Graciela M Nogueras-Gonzalez, Byron H Lee, Neema Navai, Colin P Dinney, Ashish M Kamat
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Department of Urology, University of Kentucky, Lexington, KY, USA., Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .